A new product containing secretome purified from bovine colostrum, Purasomes IRC100+, in the treatment of vaginal atrophy: in vitro study to evaluate safety and effectiveness

Abstract

Vaginal atrophy consists of the loss of elasticity and thinning of the vaginal tissues and mucous membranes. This is a condition that affects women especially during menopause, following the hormonal decline resulting from the cessation of ovarian activity. The objective of the present study was evaluated the effects of Purasomes IRC100+ on the proliferation and migration of VK2/E6E7 vaginal epithelial cells and on fibroblasts by in vitro experiments. We tested three different concentrations (0.5%, 1% and 2%). We found that cell viability was highest at 2% Purasomes IRC100+ concentration for both cell lines. The scratch-wound assay was also done. Compared with the cell scratch at 0 h, cells in all groups migrated after 24 h, the scratch was significantly reduced in treated cells compared to untreated cells. In particular, the cell migration rates were 77% and 82%, respectively for VK2/E6E7 cells and fibroblasts treated with 2% of Purasomes IRC100+. Finally, this product promotes vaginal epithelial cell proliferation and therefore it could improve vaginal atrophy and vaginal wound healing.